



# Different Clinical Presentations of Malignant Ovarian Germ Cell Tumors based on Age, Parity and Histology

Setareh Akhavan<sup>1</sup>, Jila Agah<sup>2\*</sup> and Elham Navipour<sup>3</sup>

1. Department of Gynecology Oncology, Vali-Asr Hospital, Tehran University of Medical Sciences, Tehran, Iran

2. Department of Obstetrics and Gynecology Oncology, Sabzevar University of Medical Sciences, Sabzevar, Iran

3. Sabzevar University of Medical Sciences, Sabzevar, Iran

## \* Corresponding author

### Jila Agah, MD

Department of Obstetrics and Gynecology Oncology, Sabzevar University of Medical Sciences, Sabzevar, Iran

Tel: +98 910 510 1429

Fax: +98 44 018 440

Email: jilaagah@yahoo.com

Received: Apr 11 2022

Accepted: Jul 20 2022

## Citation to this article:

Akhavan S, Agah J, Navipour E. Different Clinical Presentations of Malignant Ovarian Germ Cell Tumors based on Age, Parity and Histology. *J Iran Med Counc.* 2022;5(4):580-88.

## Abstract

**Background:** Ovarian tumors are mostly detected in advanced stages. Early diagnosis of malignant ovarian germ cell tumors is so vital to keep life and fertility of the patients. We aimed to find out different presentations of malignant ovarian germ cell tumors based on age, parity and histology to help early diagnosis of the tumors.

**Methods:** In this study, malignant ovarian germ cell tumors admitted in a referral center of gynecology oncology were studied 2001-2018. The symptoms and signs of the patients were collected and analyzed according to age, parity and specific histology.

**Results:** 128 cases of malignant germ cell tumors were detected. The primary symptoms included abdominal distension (45%), acute pain (40.95%), chronic pain (23.95%), menstrual irregularity (14.7%), sense of abdominal firmness and mass (7.72%), nausea (5.4%), fever (5.4%), lack of appetite (4.63%), virilization (3.1%), depletion of weight (3.1%), and 9.27% detected incidentally. Abdominal distension, and acute pain decreased after 24. Menstrual disorders and incidental detection in multiparas were significantly more than nulliparous ( $p < 0.05$ ). Abdominal distension was the prominent sign in dysgerminomas (50%). Almost 45% of immature, yolk sac, and mixed tumors referred with acute abdominal pain. The data showed that 85% of the patients had been suffering from some discomforts for days to months prior to the diagnosis.

**Conclusion:** The majority of cases are symptomatic for a long time before the first visit although aging and parity can lessen their severity. Late diagnosis can lead to acute abdomen in some histology types. Young women and health providers should be warned about concerned presentations of ovarian tumors.

**Keywords:** Clinical presentation, Germ cells, Histology, Ovary, Parity

## Introduction

Ovarian cancer is the most fatal gynecologic malignancy in women (1,2). The outcome of the affected women largely depends on the stage at the primary visit. Unfortunately, over 70% of these women are diagnosed in the advanced stages, when the tumor has disseminated beyond the pelvis (3). In spite of attempts to find a modality for screening the ovarian cancer, there is no approved model in this regard yet (4). Therefore, recognition of the clinical manifestations is still the sole solution for the primary detection of the tumors.

Malignant Ovarian Germ Cell Tumors (MOGCTs) account for 3% and 15% of the ovarian malignancies in the western and Asian countries, respectively. They commonly affect adolescents and young adults (5-8). Five-year survival of MOGCTs in the early stages is estimated 70-90% while it is 20-30% in the advanced stages (9). Late diagnosis of these tumors can sometimes lead to acute abdomen and emergency laparotomy due to fast overgrowth, rupture or torsion of the affected ovary which in turn can influence the cytoreduction procedures during staging or hurt the ability of fertility in the patient (10,11). Thus, having the right knowledge of the clinical manifestations in these tumors seems very important to avoid urgent situations.

“Whether the ovarian tumors are asymptomatic or the patients do not notice the symptoms” has been argued for decades. Recent reports showed that ovarian cancers are usually symptomatic but the symptoms may be neglected by the patients and/or the caregivers (9-12). Anyway, this delay can advance the stage of the tumor and consequently impact the outcome. In order to detect the disease at the early stages, we aimed to find out the associations between the symptoms of MOGCTs and age, parity and specific histology to help early diagnosis of the tumors.

## Materials and Methods

The present study was conducted in Vali-e-Asr Hospital, the main center of gynecology oncology in Tehran, Iran, during 18 years from 2001. After providing the approval of the ethics committee (IR.TUMS JKHC.Rec.1396.4819), and taking the informed consents, the cases of MOGCTs were enrolled in the study and classified according to the

histology subtypes. Using a questionnaire containing demographic and obstetric characteristics and related clinical manifestations including abdominal distention, pain, menstrual irregularity, sense of mass, nausea, urinary discomfort, fever, lack of appetite, virilization and weight depletion, the data was collected. Interview with the patients and hospital files were the references of information. The codified data were entered into the SPSS software 24, and the frequency of various symptoms and signs in whole cases and histologic subtypes via descriptive tests and correlation of symptoms with age and parity status *via* chi-square tests were analyzed.  $p$ -value<0.05 was considered significant.

## Results

128 cases of MOGCTs were detected. The mean age was  $23.88 \pm 7.85$  years. Demographic data showed that 52% had got married, and 68% were nulliparous (Table 1). Interview with the patients indicated that 85% of the cases had symptoms for days to months prior to the diagnosis. Dysgerminoma and immature teratoma for 3 days to 11 months, mixed tumors for 15 days to 11 months, yolk sac for 7 days to two months and Squamous Cell Carcinoma on teratoma (SCC teratoma) for 4 months were reported by the patients. More than 90% complained of abdominal distension and pain (Figure 1).

In 22 of the cases, the menstruation had not already been commenced and 5 cases had Dysgenetic gonads. The number of para in multipara cases included: 1 para (22), 2(11), 3(4), 5(1) and 6(2). Incidence of subtypes of MOGCTs were dysgerminoma (35.2%), immature teratomas (26.4%), mixed (15.2%), yolk sac (13.6%), SCC teratoma 4%, undifferentiated (2.4%), embryonal (1.6%), choriocarcinoma (0.8%), and carcinoid (0.8%), respectively.


About 41% referred by acute abdomen, although only 15% had sudden acute pain and 26% stated mild nonspecific symptoms in previous days. 9.27% were asymptomatic and detected incidentally (Figure 2).

Although abdominal distension, pain and menstrual disorders were the most symptoms in all age groups, their incidence declined after 24 years old, and also asymptomatic cases were increased (Figure 3).

Menstrual disorders and incidental detection in multiparas were significantly more than nulliparous

**Table 1.** Demographic characteristics of the malignant ovarian germ cell tumors

Age	Min (year)	11
	Mean (mean ± SD)	23.99±7.88
	Max (year)	50
	Others	27.6%
Education	Unlettered	6.3%
	Student (school)	32.8%
	Diploma or undergraduate	9/60%
Place of living	Urban	80%
	Rural	20%
Socio-economic status	Well-off	15.4%
	Medium	76.9%
	Poor	7.7%
Body mass index	Thin (<18.5)	25%
	Normal	53.6%
	Overweight (>24.9)	21.4%
Marital Status	Single	47.7%
	Married	52.3%
Parity	No parity	68.8%
	Parous	31.2%
Menstruation	Yes	106 (82.8%)
	No	22 (17.2%)
Menstruation disorders	Yes	43 (40.57%)
	No	63 (59.43%)
Karyotype (no menstruation- 22 cases)	Normal gonad (XX)	17 (77.27)
	Dysgenic gonad (XY)	5 (22.73)



**Figure 1.** Frequency of the histology subtypes.




Figure 2. Frequency of the symptoms and signs in malignant ovarian germ cell tumors.




Figure 3. Frequency of the symptoms and signs according to age.

**Table 2.** Comparison of the symptoms and signs in multiparas to nulliparous

	Nulliparous	Multiparas	p-value
Abdowwminal distension	43 (48.9%)	14 (35%)	0.144*
Acute pain	34 (38.6%)	16 (40%)	0.883*
Chorionic pain	22 (25%)	8 (20%)	0.536*
Menstrual irregularity	17 (19.3%)	2 (5%)	0.035*
Ascites	10 (11.4%)	2 (5%)	0.211**
Sense of abdominal firmness and mass	9 (10.2%)	1 (2.5%)	0.121**
Urinary	7 (8%)	1 (2.5%)	0.223**
Fever	6 (6.8%)	1 (2.5%)	0.296**
Nausea	6 (6.8%)	1 (2.5%)	0.296**
Torsion	5 (5.7%)	3 (7.5%)	0.482**
Lack of appetite	4 (4.5%)	2 (5%)	0.611**
Loss of weight	4 (4.5%)	-	0.219**
Hirsutism	2 (2.3%)	2 (5%)	0.37**
Incidental detection (asymptomatic)	1 (1.1%)	7 (%17.5)	0.001**
Hemoperitoneum	1 (1.1%)	1 (2.5%)	0.529**

\* Chi-square, \*\* Exact fisher.

(Table 2).

Abdominal distension and pain were the most common symptoms in all subtypes. Also, dysgerminoma and immature teratoma were the most common types which were detected incidentally. Menstrual disorders and sense of mass were more in dysgerminoma and mixed. The three undifferentiated cases referred only by acute abdomen. Torsion of mass in immature and yolk sac was more and fever was higher in immature and mixed tumors (Table 3).

## Discussion

Ovarian cancer was already entitled “silent killer” since it was frequently recognized at the advanced stages (13). This delay can obviously impact the outcome and survival of the patients. Since MOGCTs generally affect young women, it would be so vital to be diagnosed quickly. We found out that at least 85% of the patients have had symptoms for a considerable time prior to diagnosis. This is in agreement with past reports showing that 89% and 97% of women in

early and advanced stages were already symptomatic (9,14-16).

In our findings, the most common symptom at the initial visit was abdominal pain (acute and chronic). Other authors have also reported it at 55-80% (17,18). Although acute pain in our population was significantly more than other regions (41 vs. 10-25%) (19), many patients remembered that they have already had a kind of constitutional discomforts for a while. Our results revealed that acute pain was more prevalent in adolescents and young adults. It had no relationship with parity. Undifferentiated and mixed tumors were the most common subtypes showing acute abdomen which was not consistent with previous reports (20). Our dysgerminomas, similar to the past reports, were hardly associated with acute abdomen (21). Acute pain due to adnexal torsion was mostly seen in yolk sac and immature teratomas, while none of SCC. teratomas referred with adnexal torsion. Although benign teratomas were the most likely tumors to be twisted in literature (22,23), our

**Table 3.** Frequency of the symptoms and signs according to histology

	Dysgerminoma	Immature Teratoma	Yolk sac	Embryonal	Choriocarcinoma	Carcinoid	Squamous Cell Carcinoma on teratoma (SCC teratoma)	Mixed	Undifferential
Abdominal distension	22 (50%)	14 (42.4%)	8 (47.1%)	2 (100%)	-	-	3 (60%)	7 (36.8%)	-
Acute pain	11 (25%)	15 (45.5%)	8 (47.1%)	1 (50%)	1 (100%)	-	2 (40%)	8 (42.1%)	3 (100%)
Chronic pain	9 (20.5%)	9 (27.3%)	4 (23.5%)	-	1 (100%)	-	2 (40%)	4 (21.1%)	-
Menstrual disorder	9 (20.5%)	5 (15.2%)	1 (5.9%)	-	-	-	-	4 (21.1%)	-
Sense of abdominal firmness and mass	5 (11.4%)	1 (3%)	1 (5.9%)	-	-	-	-	3 (15.8%)	-
Ascites	5 (11.4%)	1 (3%)	4 (23.5%)	-	-	-	-	2 (10.5%)	-
Urinary	4 (9.1%)	1 (3%)	2 (11.8%)	-	-	-	1 (20%)	-	-
Incidental detection (asymptomatic)	3 (6.8%)	4 (12.1%)	-	-	-	-	-	1 (5.3%)	-
Torsion	2 (4.5%)	4 (12.1%)	2 (11.8%)	-	-	-	-	-	-
Nausea	2 (4.5%)	2 (6.1%)	1 (5.9%)	-	-	-	-	2 (10.5%)	-
Hirsutism	2 (4.5%)	-	1 (5.9%)	-	-	-	-	1 (5.3%)	-
Loss of weight	2 (4.5%)	-	1 (5.9%)	-	-	-	-	1 (5.3%)	-
Lack of appetite	1 (2.3%)	3 (9.1%)	1 (5.9%)	-	-	-	-	1 (5.3%)	-
Fever	1 (2.3%)	2 (6.1%)	3 (17.6%)	-	-	-	-	1 (14.3%)	-
Hemoperitoneum	1 (2.3%)	-	1(5.9)	-	-	-	-	-	-

malignant teratomas showed diverse behaviors in this regard.

Abdominal distention has been reported at 45-85% in different reports (17-19), and we found it at 45%. Mixed tumors were the most common types involved with abdominal distention which confirmed other reports (20). We found its peak at 20 which was decreased sharply after that. It can be attributed to limited bony skeleton of adolescents leading to fast extension of ovarian tumors into the abdomen (24). We found out that multiparas had less complaints

of abdominal distention compared to nulliparas, although the difference was not significant.

Hormonal imbalance due to the secretions of human chorionic gonadotropin (HCG), estrogen or androgen from germ cell tumors can induce menstrual irregularity, hirsutism or precocious puberty (25,26). The incidence of menstrual irregularity in our cases was parallel to other surveys (14.7 vs. 16.9%) (17). It was more in adolescents and young adults, and interestingly, nulliparas were significantly more involved with menstrual irregularity. According to

histology, dysgerminomas, immature teratomas and mixed tumors were the most in this regard. On the other hand, germ cell tumors may be discovered in adolescents with primary amenorrhea which warrants assessment of karyotype to detect dysgenetic gonads. Regarding the risk of malignancy in dysgenetic gonads, in 30-50% bilateral ovariectomy should be considered (27-29). We faced five cases of primary amenorrhea who owned 46 XY chromosomes, three of which had mixed tumors, and two cases had pure dysgerminomas.

Other symptoms and signs like urinary and gastrointestinal complaints, fever, low appetite and weight loss were very limited in the patients which is in agreement with the previous studies (17,25) Importantly, 9.2% of the cases were asymptomatic and detected incidentally (during ultrasonography for another problem). It was more common in immature teratomas. Asymptomatic cases were significantly more in multiparas and older women. It can be associated with limited pelvic capacity in adolescents which cause fast expansion of tumor into the abdomen and incidence of clinical manifestations (24).

## Conclusion

Malignant ovarian germ cell tumors can represent nonspecific various symptoms which can differ in point of severity and duration according to

histology, age and parity. Pain, abdominal distention and menstrual irregularity are the most common symptoms. Women over 20-25 years, and multiparas may be less symptomatic or even asymptomatic. These tumors can produce acute abdomen due to late diagnosis which is higher in adolescents. However, it should be considered that a considerable number of patients may be symptomatic for days to even months prior to the first approach. Education of different presentations of malignant ovarian germ cell tumors to target populations and also health providers can help to avoid late diagnosis of the disease and establish the life and fertility of many young women worldwide.

## Ethical issues

(IR.TUMS JKHC.Rec.1396.4819).

## Acknowledgements

Hereby, we extend our gratitude to all the patients for their cooperation. We would also like to thank the chief and staff of Vali-e-Asr Hospital in Tehran, Iran for assisting us in the data collection.

## Conflict of Interest

The authors declare that they have no conflicts of interest.

---

## References

1. Chowdhury S, Jahan R, Hossain DL, Joty FS, Rahman S, Dewan F. Pre-operative assessment of ovarian tumor in patients presenting with adnexal mass on the basis of risk of malignancy index (RMI). *J Shaheed Suhrawardy Med College* 2017;9(2):69-73.
2. Akhavan S, Agah J, Alipour A. Frequency of malignant ovarian germ cell tumor and distribution of demographic features in a main tertiary hospital in Iran. *Journal of Obstetrics, Gynecology and Cancer Research (JOGCR)* 2018 Jun 10;3(2):59-63.
3. Takayasu H, Masumoto K, Tanaka N, Aiyoshi T, Sasaki T, Ono K, et al. A clinical review of ovarian tumors in children and adolescents. *Pediatr Surg Int* 2020 Jun;36(6):701-9.
4. Goff B, Muntz H. Screening and early diagnosis of ovarian cancer. *Women's Health Primary Care* 2005;8(6):262-8.
5. Torre LA, Trabert B, DeSantis CE, Miller KD, Samimi G, Runowicz CD, et al. Ovarian cancer statistics, 2018. *CA Cancer J Clin* 2018 Jul;68(4):284-96.
6. Low JJ, Ilancheran A, Ng JS. Malignant ovarian germ-cell tumours. *Best Pract Res Clin Obstet Gynaecol* 2012

Jun;26(3):347-55.

7. Bixel KL, Fowler J. Ovarian germ cell tumors. *Gynecologic Care* 2018 Feb 15:350.
8. Abu-Zaid A, Nazer A, AlOmar O, Azzam A, Al-Eid HS, Elhassan TA, et al. Incidence of malignant ovarian germ cell tumors (MOGCTs) in Saudi Arabia. *Hematol Oncol Stem Cell Ther* 2014 Mar;7(1):41-3.
9. Derquin F, Floquet A, Hardy-Bessard A, Edeline J, Lotz J, Alexandre J, et al. Need for risk-adapted therapy for malignant ovarian germ cell tumors: a large multicenter analysis of germ cell tumors' patients from French TMRG network. *Gynecol Oncol* 2020 Sep;158(3):666-72.
10. Mangili G, Sigismondi C, Scollo P, Ferrandina G, Candiani M, Angioli R, et al. Management of bilateral malignant ovarian germ cell tumors: a MITO-9 retrospective study. *Int J Gynecol Cancer* 2015 Feb;25(2):203-7.
11. Nasioudis D, Minis E, Chapman-Davis E, Frey MK, Caputo TA, Witkin SS, et al. Minimally invasive staging of apparent stage I malignant ovarian germ cell tumors: prevalence and outcomes. *J Minim Invasive Gynecol* 2019 Mar-Apr;26(3):471-6.
12. Jacobs IJ, Menon U, Ryan A, Gentry-Maharaj A, Burnell M, Kalsi JK, et al. Ovarian cancer screening and mortality in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): a randomised controlled trial. *Lancet* 2016 Mar 5;387(10022):945-56.
13. Smith HO, Berwick M, Verschraegen CF, Wiggins C, Lansing L, Muller CY, et al. Incidence and survival rates for female malignant germ cell tumors. *Obstet Gynecol* 2006 May;107(5):1075-85.
14. Goff BA, Mandel LS, Drescher CW, Urban N, Gough S, Schurman KM, et al. Development of an ovarian cancer symptom index: possibilities for earlier detection. *Cancer* 2007 Jan 15;109(2):221-7.
15. Wang J, Zhuo X, Yang J, Cao D, Shen K, Huang H, et al. Outcomes and prognostic factors of patients with recurrent and persistent malignant ovarian germ cell tumors. *Arch Gynecol Obstet* 2020 Apr;301(4):1021-6.
16. Agah J, Jafarzadeh Esfehiani R, Kamalimanesh B, Fattahi Abdzadeh M, Jalilian AR. Mismanagement of a huge ovarian serous cystadenoma in a young girl; a case report. *J Midwifery Reprod Health* 2015 Jan 1;3(1):315-7.
17. Sood A, Daver RG, Tambe SG. Epidemiology of ovarian malignancies. *Int J Reprod Contraception Obstet Gynecol* 2016;5(1):187-93.
18. Tewari K, Cappuccini F, Disaia PJ, Berman ML, Manetta A, Kohler MF. Malignant germ cell tumors of the ovary. *Obstet Gynecol* 2000 Jan;95(1):128-33.
19. Ali A, Sayed H, Salem M, Hamdy M, Farok A. Clinicopathological pattern and outcome of pediatric malignant ovarian germ cell tumors: South Egypt Cancer Institute experience. *J Pediatr Surg* 2018 Apr;53(4):837-40.
20. Goyal LD, Kaur S, Kawatra K. Malignant mixed germ cell tumour of ovary—an unusual combination and review of literature. *J Ovarian Res* 2014 Nov 4;7:91.
21. Michael KK, Wampler K, Underwood J, Hansen C. Ovarian dysgerminoma: a case study. *J Diagnostic Med Sonography* 2015 Sep;31(5):327-30.
22. Chan JK, Gardner AB, Chan JE, Guan A, Alshak M, Kapp DS. The influence of age and other prognostic factors associated with survival of ovarian immature teratoma—A study of 1307 patients. *Gynecol Oncol* 2016 Sep;142(3):446-51.
23. Alwazzan AB, Popowich S, Dean E, Robinson C, Lotocki R, Altman AD. Pure immature teratoma of the ovary in adults: thirty-year experience of a single tertiary care center. *Int J Gynecol Cancer* 2015 Nov;25(9):1616-22.
24. Tanwar RK, Saxena B, Mohanpuria SL, Goyal H, Agarwal L, Saxena M, et al. Malignant ovarian germ cell tumors in pediatric age group: a clinicopathological study over 21 years in eastern Rajasthan (India). *Cancer Res* 2020;8(4):57-61.
25. Lakshmanan M, Gupta S, Kumar V, Akhtar N, Chaturvedi A, Misra S, et al. Germ cell tumor ovary: an institutional

experience of treatment and survival outcomes. *Indian J Surg Oncol* 2018 Jun;9(2):215-9.

26. Nogales FF, Dulcey I, Preda O. Germ cell tumors of the ovary: an update. *Arch Pathol Lab Med* 2014 Mar;138(3):351-62.

27. Wang X, Ma Z, Li Y. Ovarian yolk sac tumor: the experience of a regional cancer center. *Int J Gynecol Cancer* 2016 Jun;26(5):884-91.

28. Berglund A, Johannsen TH, Stochholm K, Viuff MH, Fedder J, Main KM, et al. Incidence, prevalence, diagnostic delay, and clinical presentation of female 46, XY disorders of sex development. *J Clin Endocrinol Metab* 2016 Dec;101(12):4532-40.

29. Cools M, Looijenga LH, Wolffenbuttel KP, T'Sjoen G. Managing the risk of germ cell tumourigenesis in disorders of sex development patients. *Endocr Dev* 2014;27:185-96.